Navigation Links
CuraGen Reports First Quarter 2009 Financial Results
Date:4/23/2009

BRANFORD, Conn., April 23 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), today reported its financial results for the first quarter of 2009.

During the three month period ended March 31, 2009, CuraGen utilized $4.1 million of cash and investments for operations and repurchased $4.8 million of debt for $3.8 million and ended the first quarter with $80 million of cash and investments. As of March 31, 2009, CuraGen had $14 million of outstanding 4% convertible subordinated notes due February 2011. For the quarter ended March 31, 2009, CuraGen reported total operating expenses of $3.6 million, compared to total operating expenses of $7.1 million during the same period in 2008. CuraGen expects to use $3 to $4 million of cash and investments in the second quarter of 2009 to fund operations, consistent with previous guidance, and also expects to end the second quarter of 2009 with between $76 and $77 million of cash and investments.

"We currently have $80 million of cash and investments on hand and an attractive Phase II development asset that continues to show promising activity in metastatic melanoma and early activity in breast cancer. Abstracts on these studies have been accepted for presentation at the Annual Meeting of the American Society of Clinical Oncology in Orlando, FL (May 29 to June 2, 2009), where we expect to report final results of our Phase II melanoma trial and initial results of our breast cancer trial," commented Dr. Timothy M. Shannon, President and Chief Executive Officer.

As previously announced on February 18, 2009, the Company's Board of Directors is in the process of evaluating strategic alternatives. While the process is underway, the Company does not intend to or expect to disclose any developments regarding the process until, if ever, a definitive agreement is entered into or the Board decides to terminate the process.

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to CuraGen's revenue, expenses, depreciation, amortization, asset impairment charges, losses, income, future cash and investment positions and cash burn rate, the timing and expected results of our clinical programs, and the development and marketability of planned drugs, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CRGN-F

                         - FINANCIAL TABLES ATTACHED -



                              CURAGEN CORPORATION
                      CONDENSED STATEMENTS OF OPERATIONS
                     (in thousands, except per share data)



                                          Three Months Ended
                                              March 31,
                                              ---------
                                          2009          2008
                                          ----          ----
                                           (unaudited)

    Collaboration revenue                   $-           $22

    Operating expenses:
      Research and development           1,682         5,371
      General and administrative         1,906         1,715
                                         -----         -----
        Total operating expenses             4             7
                                         -----         -----

    Loss from operations                    (4)           (7)
    Interest income                          0             1
    Interest expense                      (175)         (797)
    Realized gain (loss) on
     sale of available-for-
     sale investments, net                  84            (4)
    Gain on extinguishment of debt         962             -
                                           ---          ----

    Loss before income tax benefit          (2)           (7)
    Income tax benefit                     726            18
                                           ---            --

    Net loss                               ($2)          ($7)
                                           ===           ===

    Basic net loss per share            $(0.03)       $(0.12)
                                        ======        ======

    Weighted average number
     of shares used in
     computing basic net loss
     per share                          56,967        56,520
                                        ======        ======




                            SELECTED BALANCE SHEET INFORMATION


                                           March 31,   December 31,
                                              2009          2008
                                              ----          ----
                                                (unaudited)

    Cash and investments                    $79,792       $87,664
                                            =======       =======

    Working capital                         $78,153        84,044
                                            =======        ======

    Total assets                            $80,568        88,546
                                            =======        ======

    4% Convertible
     subordinated notes due 2011            $14,142        18,967
                                            =======        ======

    Total long-term liabilities             $14,142        18,967
                                            =======        ======

    Accumulated deficit                    $464,330       462,793
                                           ========       =======

    Stockholders' equity                    $64,309        65,465
                                            =======        ======

    Contacts:
    Sean Cassidy
    Vice President and Chief Financial Officer
    scassidy@curagen.com
    203 871-4400


'/>"/>
SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CuraGen to Present at the Rodman & Renshaw Annual Global Investment Conference
2. CuraGen to Present at The Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
3. CuraGen Corporation Regains NASDAQ Listing Compliance
4. CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million
5. CuraGen Reports First Quarter 2008 Financial Results
6. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
7. CuraGen Reports Third Quarter 2007 Financial Results
8. CuraGen to Present at the Bear Stearns 20th Annual Healthcare Conference
9. NuVasive Reports First Quarter 2009 Financial Results
10. Torchmark Corporation Reports First Quarter 2009 Results
11. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... ... The Lung Institute has partnered with the Gulfcoast North Area ... at their clinic in downtown Tampa. The class is complimentary for the public. Register ... a free downloadable 4 Week Smoking Cessation Guide for those who are ...
(Date:5/26/2016)... ... 26, 2016 , ... American orthopedic surgeon and internationally recognized ... Horizon International (BHI), Brian Mehling, M.D., spoke at an International Conference and Expo ... in Chicago, IL, USA. Dr. Mehling’s presentation was focused on stem cell therapy ...
(Date:5/26/2016)... TN (PRWEB) , ... May 26, 2016 , ... ... fitness education and products recently hosted the first PowerWave Instructor Certification Course in ... who lead a group of fitness professional through the 8 hour interactive course ...
(Date:5/26/2016)... ... 2016 , ... On May 23rd during the National Eye Institute’s “Healthy Vision ... advocate, was honored by Ashram, Inc. as the world’s foremost water visionary. , “Sharon ... banks of the Nile to fill their red clay pots with life-sustaining water.” Said ...
(Date:5/26/2016)... ... May 26, 2016 , ... Workrite Ergonomics ... leadership and to further develop their rapidly expanding portfolio of customer and end ... a concentration in Marketing and an M.B.A. with concentration in management from Bryant ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... Frankfurt Prime Standard: QIA) today announced that the company has ... GmbH to develop and commercialize predictive assays in oncology. An ... a marker to predict effectiveness of anthracycline treatment in triple ... are pleased to partner with Therawis, which developed the PITX2 ...
Breaking Medicine Technology: